Scans

Tools

Home

Charts

Watchlist

Products

Zim Laboratories Ltd

ZIMLAB

NSE

₹138.17-4.55%19 Oct 2026 at 3:51 PM

Reports

Pharma Formulations

Zim Laboratories Ltd

ZIMLAB

NSE

₹138.17

-4.55%

19 Oct 2026 at 3:51 PM

SOICxStockScans Reports

Ask AI

Pharma Formulations

Indices

Business Overview: What the company does, in plain English.Growth Catalysts: The forward growth drivers and triggers.Guidance Report: Management guidance vs outcomes.Forensic Report: Accounting quality and red flags.Deep Dive Report: In-depth business analysis.

ZIM Laboratories is a research-driven pharmaceutical company that makes complex generic medicines in easy-to-take oral forms - tablets, capsules, powders and dissolving films - using its own patented, non-infringing manufacturing technologies. Founded in 1984 by a pharmaceutical chemist who returned to Nagpur to build the business, it has evolved from a government tender supplier into a global exporter of differentiated generics across more than 50 countries. The recurring approach is to avoid plain-vanilla generics that compete on price, and instead develop “smarter generics or super generics” - products with unique delivery mechanisms that can be created faster and cheaper than novel drugs, then licensed to local partners who handle the selling.

Business segments

Three engines at different stages - a differentiated generics cash cow that supplies intermediates and finished pills to partners worldwide, a high-value innovation pipeline of next-generation complex molecules, and a consumer-wellness bet built on the same film technology - all fed by a single R&D and manufacturing backbone.

1. Differentiated generic pharmaceuticals: the partner-supply engine that funds everything else

ZIM makes complex oral-solid medicines and the intermediates that go into them, then licenses the dossiers and supplies the products to distribution partners who take them to market - it owns the factory and the science, not the sales force.

Two product forms, one model - the business sells Pre-Formulation Intermediates (pellets, granules and taste-masked powders that clients turn into finished drugs) and Finished Formulations (tablets, capsules, dry syrups and oral thin films ready for pharmacy shelves); PFI targets countries that restrict direct imports of finished medicines, while FF goes to markets where ZIM’s partners register the products under their own or ZIM’s brand.
No feet on the street - instead of building its own sales force, ZIM uses a business-development team to find local distributors and marketing companies, transfers the Marketing Authorisation to them, and signs long-term supply agreements that last “as long as the business will be there”; the technology never leaves ZIM’s own plant.
The moat is non-infringing know-how - four proprietary technology platforms (with names like Micro-Emulsion Coating and Pellet Cold Forming) let ZIM make differentiated generics without stepping on existing patents, so partners get a product with a competitive edge and ZIM avoids the price wars of common generics.
Three plants, one campus - all manufacturing happens in Nagpur across a 100,000 sq. ft. general oral-dosage facility, a dedicated cephalosporin block and a compact oral-thin-film plant; together they hold WHO-GMP and ISO certifications, though EU-GMP accreditation was paused during FY26 after an audit and is being remediated.

2. New Innovative Products: the high-stakes pipeline of first-to-market complex generics

These are next-generation, non-infringing versions of large-market drugs - developed in-house, filed mainly in Europe, and designed to be among the first generics available when patents expire.

Twelve shots on goal - ZIM has fully developed a dozen NIP molecules targeting markets worth hundreds of millions to several billion dollars each, spanning urology, gastrointestinal, anti-coagulant, central-nervous-system, rheumatoid-arthritis, anti-infective, analgesics/pain and skin-disorders therapies.
Europe is the proving ground - eight NIPs have been filed in the European Union so far, and three have already received Marketing Authorisations there: a blood-thinner (Dabigatran Etexilate) approved in Italy, a multiple-sclerosis drug (Di-Methyl Fumarate) and an anti-infective oral suspension (Azithromycin).
Revenue comes from licensing first, supply later - the model earns dossier-licensing fees upfront and then manufacturing-and-supply revenue once the partner launches; in FY26 NIP and dossier-licensing income together contributed about ₹267 million, or 7% of total operating income.
One product already has Indian regulatory approval - a fixed-dose combination of Naproxen and Esomeprazole in a single capsule, using ZIM’s delayed-release mini-tablet and pellet technology, received Indian regulatory approval in late 2025 and is headed for commercial launch through a domestic pharmaceutical company.

3. Oral Thin Films: the patient-friendly format that opens both pharma and wellness markets

ZIM’s patented Thinoral® technology turns medicines and supplements into postage-stamp-sized strips that dissolve instantly on the tongue - no water, no swallowing, and a growing list of branded deals in Europe, Latin America and Australia.

A platform, not a single product - the OTF engine spans prescription drugs (like Rizatriptan for migraines and Sildenafil for erectile dysfunction), nutraceuticals (Vitamin D3, Melatonin, Vitamin B12) and a pipeline of sublingual and mucoadhesive films that absorb directly through the mouth’s lining.
Technology out-licensing is the newest lever - in a landmark 2025 deal, ZIM licensed its ThinOral® know-how to UAE-based Globalpharma, which will register and eventually manufacture ten OTF products locally using ZIM’s ready-to-use powder mixes; an earlier exclusive deal put Vitamin D3 film into Brazil’s number-one vitamin-D brand.
Regulated-market beachheads are opening - the first European commercial order (Sildenafil film) shipped to Italy and Malta in FY24; Australia granted its first Marketing Authorisation for Rizatriptan Benzoate Orally Disintegrating Strips in mid-2025; and a co-development partner, Neuraxpharm, secured an EU-wide approval for Buprenorphine sublingual films.
A dedicated plant with a hiccup - the 6,300 sq. ft. OTF facility can produce 324 million strips a year and holds ISO 9001 and NSF-ANSI 455-2 certifications, though an EU inspection in early FY26 raised observations that deferred a German launch; corrective actions were submitted and accepted.

4. Nutraceuticals: the consumer-wellness extension of the same factory and science

ZIM takes the pellet and film technologies built for prescription drugs and applies them to vitamins and dietary supplements, selling under its own ZimUNaT brand through e-commerce and government channels.

Same dosage forms, different customer - the nutraceutical range uses pellets-in-capsules and oral thin films to deliver supplements for eye care, cognition, blood-sugar support, anti-ageing and more; the business grew out of supplying distinctive PFIs to nutraceutical clients and now sells finished branded products directly.
Omnichannel, but asset-light - ZimUNaT products are sold on Indian e-commerce platforms like Tata 1mg, Amazon and Flipkart, and the company also supplies government procurement schemes; it is building an omnichannel strategy that integrates offline distribution networks.
Certified for quality - the nutraceutical operation holds NSF GMP certification for dietary supplements and is registered with the US FDA, and a recent capital-expenditure project added a liquid-in-pellet technology suite to expand the product range.

Group structure and partners

ZIM operates through a single listed entity in India with a ring of small, wholly owned subsidiaries in the UAE, Europe, Australia and soon Chile - each one exists to hold registrations, manage regulatory filings and get products into local markets.

Latvia for Europe - SIA ZIM Laboratories Limited manages product registrations and marketing in the EU, and has secured Manufacturing and Marketing Authorisations from Portuguese and Italian regulators for ZIM’s OTF and NIP products.
Australia for Oceania - ZIMTAS Pty Ltd, now 99.96% owned, holds Marketing Authorisations for two products and received the company’s first Australian approval in mid-2025.
Two Indian subsidiaries for focus - ZIM Health Technologies Limited acts as an extended R&D arm, while ZIM Thinorals Private Limited was incorporated to house the OTF business and is yet to commence operations.
A newly formed advisory board - constituted in March 2026, it brings three heavyweights with decades of leadership at GSK Pharma, UCB Pharma and private-equity advisory to guide strategy, without executive powers.

Quick Ratios

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Peer Comparison

Quick Ratios

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Peer Comparison

Price

Charts

Documents

Edit Ratios

Mkt Cap

Market Capitalization

₹729Cr

Close Price

₹135.81

Industry

Pharma Formulations

Price To Earnings

165.62

Price To Sales

1.84

Revenue

₹397Cr

Rev Gr TTM

Revenue Growth TTM

7.55%

PAT Gr TTM

PAT Growth TTM

-60.60%

Consolidated

Standalone

Numbers

Percentage

Quarter	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue RevenueCr	86	96	118	82	92	96	109	72	89	109	105	94
Growth YoY Revenue Growth YoY%	-13.7	-4.6	11.8	21.3	7.3	0.0	-7.8	-12.3	-3.7	12.8	-3.2	31.2
Expenses ExpensesCr	77	85	102	74	83	85	94	68	83	96	98	92
Operating Profit Operating ProfitCr	9	12	16	8	10	12	15	4	6	13	7	2
OPM OPM%	10.9	12.0	13.3	9.8	10.3	12.0	13.4	5.9	6.5	11.8	6.8	2.6
Other Income Other IncomeCr	1	1	2	1	1	2	2	1	2	2	6	1
Interest Expense Interest ExpenseCr	1	2	2	3	3	3	3	3	3	3	3	4
Depreciation DepreciationCr	4	4	4	5	5	5	5	5	5	5	5	5
PBT PBTCr	5	7	11	1	3	6	8	-2	0	6	5	-6
Tax TaxCr	1	2	3	0	1	2	3	-1	0	2	1	-2
PAT PATCr	4	5	8	1	2	4	5	-2	0	4	4	-4
Growth YoY PAT Growth YoY%	-23.9	-27.6	11.7	291.3	-42.6	-16.3	-39.7	-307.8	-117.7	10.0	-23.4	-115.0
NPM NPM%	4.8	5.0	6.9	1.1	2.6	4.2	4.5	-2.6	-0.5	4.0	3.5	-4.3
EPS EPS₹	0.8	1.0	1.7	0.2	0.5	0.8	1.0	-0.4	-0.1	0.9	0.8	-0.8

Quarter	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue RevenueCr	86	96	118	82	92	96	109	72	89	109	105	94
Growth YoY Revenue Growth YoY%	-13.7	-4.6	11.8	21.3	7.3	0.0	-7.8	-12.3	-3.7	12.8	-3.2	31.2
Expenses ExpensesCr	77	85	102	74	83	85	94	68	83	96	98	92
Operating Profit Operating ProfitCr	9	12	16	8	10	12	15	4	6	13	7	2
OPM OPM%	10.9	12.0	13.3	9.8	10.3	12.0	13.4	5.9	6.5	11.8	6.8	2.6
Other Income Other IncomeCr	1	1	2	1	1	2	2	1	2	2	6	1
Interest Expense Interest ExpenseCr	1	2	2	3	3	3	3	3	3	3	3	4
Depreciation DepreciationCr	4	4	4	5	5	5	5	5	5	5	5	5
PBT PBTCr	5	7	11	1	3	6	8	-2	0	6	5	-6
Tax TaxCr	1	2	3	0	1	2	3	-1	0	2	1	-2
PAT PATCr	4	5	8	1	2	4	5	-2	0	4	4	-4
Growth YoY PAT Growth YoY%	-23.9	-27.6	11.7	291.3	-42.6	-16.3	-39.7	-307.8	-117.7	10.0	-23.4	-115.0
NPM NPM%	4.8	5.0	6.9	1.1	2.6	4.2	4.5	-2.6	-0.5	4.0	3.5	-4.3
EPS EPS₹	0.8	1.0	1.7	0.2	0.5	0.8	1.0	-0.4	-0.1	0.9	0.8	-0.8

Consolidated

Standalone

Numbers

Percentage

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Revenue RevenueCr	269	235	273	335	278	307	333	399	367	379	374	397
Growth Revenue Growth%	0.8	-12.5	16.1	22.9	-17.2	10.6	8.5	19.5	-7.8	3.2	-1.2	7.5
Expenses ExpensesCr	239	204	238	293	255	268	292	347	326	335	344	369
Operating Profit Operating ProfitCr	29	31	35	42	23	40	41	52	41	44	30	28
OPM OPM%	10.9	13.4	12.8	12.5	8.1	12.9	12.3	13.0	11.3	11.5	8.0	7.1
Other Income Other IncomeCr	-1	5	9	2	5	-3	4	6	5	6	11	11
Interest Expense Interest ExpenseCr	14	10	9	11	13	11	8	6	7	11	13	14
Depreciation DepreciationCr	9	9	10	11	14	16	16	17	16	20	20	20
PBT PBTCr	5	18	25	22	0	10	21	35	24	18	8	5
Tax TaxCr	0	-1	6	7	-3	3	6	11	6	6	2	1
PAT PATCr	5	19	19	15	3	7	15	24	17	12	6	4
Growth PAT Growth%	123.6	264.6	2.8	-19.7	-78.5	122.0	98.8	67.9	-29.4	-29.5	-52.0	-60.6
NPM NPM%	1.9	7.9	7.0	4.6	1.2	2.4	4.4	6.1	4.7	3.2	1.6	0.9
EPS EPS₹	6.4	23.2	11.9	3.2	0.7	1.5	3.0	5.0	3.5	2.5	1.2	0.8

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Revenue RevenueCr	269	235	273	335	278	307	333	399	367	379	374	397
Growth Revenue Growth%	0.8	-12.5	16.1	22.9	-17.2	10.6	8.5	19.5	-7.8	3.2	-1.2	7.5
Expenses ExpensesCr	239	204	238	293	255	268	292	347	326	335	344	369
Operating Profit Operating ProfitCr	29	31	35	42	23	40	41	52	41	44	30	28
OPM OPM%	10.9	13.4	12.8	12.5	8.1	12.9	12.3	13.0	11.3	11.5	8.0	7.1
Other Income Other IncomeCr	-1	5	9	2	5	-3	4	6	5	6	11	11
Interest Expense Interest ExpenseCr	14	10	9	11	13	11	8	6	7	11	13	14
Depreciation DepreciationCr	9	9	10	11	14	16	16	17	16	20	20	20
PBT PBTCr	5	18	25	22	0	10	21	35	24	18	8	5
Tax TaxCr	0	-1	6	7	-3	3	6	11	6	6	2	1
PAT PATCr	5	19	19	15	3	7	15	24	17	12	6	4
Growth PAT Growth%	123.6	264.6	2.8	-19.7	-78.5	122.0	98.8	67.9	-29.4	-29.5	-52.0	-60.6
NPM NPM%	1.9	7.9	7.0	4.6	1.2	2.4	4.4	6.1	4.7	3.2	1.6	0.9
EPS EPS₹	6.4	23.2	11.9	3.2	0.7	1.5	3.0	5.0	3.5	2.5	1.2	0.8

Consolidated

Standalone

Numbers

Percentage

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital Equity CapitalCr	8	8	8	16	16	16	16	49	49	49	54
Reserves ReservesCr	91	110	129	135	138	145	159	152	190	202	240
Current Liabilities Current LiabilitiesCr	122	113	141	155	143	142	146	111	159	166	190
Non Current Liabilities Non Current LiabilitiesCr	35	28	20	22	28	22	20	30	49	54	53
Total Liabilities Total LiabilitiesCr	256	259	298	328	325	325	342	342	447	472	539
Current Assets Current AssetsCr	154	154	173	194	182	192	212	191	228	231	276
Non Current Assets Non Current AssetsCr	102	105	125	134	143	133	129	151	219	241	264
Total Assets Total AssetsCr	256	259	298	328	325	325	342	342	447	472	539

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital Equity CapitalCr	8	8	8	16	16	16	16	49	49	49	54
Reserves ReservesCr	91	110	129	135	138	145	159	152	190	202	240
Current Liabilities Current LiabilitiesCr	122	113	141	155	143	142	146	111	159	166	190
Non Current Liabilities Non Current LiabilitiesCr	35	28	20	22	28	22	20	30	49	54	53
Total Liabilities Total LiabilitiesCr	256	259	298	328	325	325	342	342	447	472	539
Current Assets Current AssetsCr	154	154	173	194	182	192	212	191	228	231	276
Non Current Assets Non Current AssetsCr	102	105	125	134	143	133	129	151	219	241	264
Total Assets Total AssetsCr	256	259	298	328	325	325	342	342	447	472	539

Consolidated

Standalone

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow Operating Cash FlowCr	22	32	37	35	22	32	49	38	16	41	50
Investing Cash Flow Investing Cash FlowCr	-12	-7	-26	-21	-19	-6	-15	-36	-73	-40	-56
Financing Cash Flow Financing Cash FlowCr	-10	-25	-10	-15	-3	-26	-33	1	60	-9	28
Net Cash Flow Net Cash FlowCr	0	0	1	-1	1	0	2	3	3	-8	23
Free Cash Flow Free Cash FlowCr	9	24	8	15	3	25	34	1	-57	1	11
CFO To PAT CFO To PAT%	430.5	172.6	191.9	227.7	664.8	435.3	338.2	153.6	94.4	338.3	848.5
CFO To EBITDA CFO To EBITDA%	75.2	101.9	105.4	83.1	96.9	80.1	120.1	72.2	39.4	94.1	165.1

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow Operating Cash FlowCr	22	32	37	35	22	32	49	38	16	41	50
Investing Cash Flow Investing Cash FlowCr	-12	-7	-26	-21	-19	-6	-15	-36	-73	-40	-56
Financing Cash Flow Financing Cash FlowCr	-10	-25	-10	-15	-3	-26	-33	1	60	-9	28
Net Cash Flow Net Cash FlowCr	0	0	1	-1	1	0	2	3	3	-8	23
Free Cash Flow Free Cash FlowCr	9	24	8	15	3	25	34	1	-57	1	11
CFO To PAT CFO To PAT%	430.5	172.6	191.9	227.7	664.8	435.3	338.2	153.6	94.4	338.3	848.5
CFO To EBITDA CFO To EBITDA%	75.2	101.9	105.4	83.1	96.9	80.1	120.1	72.2	39.4	94.1	165.1

Consolidated

Standalone

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Current
Valuation Ratios Valuation Ratios
Market Cap Market CapitalizationCr				202	91	118	260	353	465	391	320	729
Price To Earnings Price To Earnings				13.2	27.4	16.1	17.8	14.4	27.0	32.1	54.9	165.6
Price To Sales Price To Sales				0.6	0.3	0.4	0.8	0.9	1.3	1.0	0.9	1.8
Price To Book Price To Book				1.3	0.6	0.7	1.5	1.8	1.9	1.6	1.1	2.5
EV To EBITDA EV To EBITDA				6.2	7.2	4.8	7.5	7.8	13.7	11.6	13.4	30.5
Profitability Ratios Profitability Ratios
GPM GPM%	37.2	45.0	44.5	48.3	43.5	39.9	42.0	40.5	41.0	42.6	40.7	40.7
OPM OPM%	10.9	13.4	12.8	12.5	8.1	12.9	12.3	13.0	11.3	11.5	8.0	7.1
NPM NPM%	1.9	7.9	7.0	4.6	1.2	2.4	4.4	6.1	4.7	3.2	1.6	0.9
ROCE ROCE%	10.0	14.2	16.6	15.3	5.5	8.7	12.8	15.6	8.7	8.0	5.1	5.1
ROE ROE%	5.2	15.7	14.0	10.2	2.1	4.5	8.3	12.2	7.2	4.8	2.0	2.0
ROA ROA%	2.0	7.2	6.4	4.7	1.0	2.3	4.3	7.2	3.9	2.6	1.1	1.1
Operational Ratios Operational Ratios
Solvency Ratios Solvency Ratios
Liquidity Ratios Liquidity Ratios

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Current
Valuation Ratios Valuation Ratios
Market Cap Market CapitalizationCr				202	91	118	260	353	465	391	320	729
Price To Earnings Price To Earnings				13.2	27.4	16.1	17.8	14.4	27.0	32.1	54.9	165.6
Price To Sales Price To Sales				0.6	0.3	0.4	0.8	0.9	1.3	1.0	0.9	1.8
Price To Book Price To Book				1.3	0.6	0.7	1.5	1.8	1.9	1.6	1.1	2.5
EV To EBITDA EV To EBITDA				6.2	7.2	4.8	7.5	7.8	13.7	11.6	13.4	30.5
Profitability Ratios Profitability Ratios
GPM GPM%	37.2	45.0	44.5	48.3	43.5	39.9	42.0	40.5	41.0	42.6	40.7	40.7
OPM OPM%	10.9	13.4	12.8	12.5	8.1	12.9	12.3	13.0	11.3	11.5	8.0	7.1
NPM NPM%	1.9	7.9	7.0	4.6	1.2	2.4	4.4	6.1	4.7	3.2	1.6	0.9
ROCE ROCE%	10.0	14.2	16.6	15.3	5.5	8.7	12.8	15.6	8.7	8.0	5.1	5.1
ROE ROE%	5.2	15.7	14.0	10.2	2.1	4.5	8.3	12.2	7.2	4.8	2.0	2.0
ROA ROA%	2.0	7.2	6.4	4.7	1.0	2.3	4.3	7.2	3.9	2.6	1.1	1.1
Operational Ratios Operational Ratios
Solvency Ratios Solvency Ratios
Liquidity Ratios Liquidity Ratios

	LINCOLN	THEMISMED	KILITCH	ZIMLAB	INFLUX	TLL	ALBERTDAVD
Market CapitalizationMkt CapCr	1,068	924	766	729	593	481	454
Close PriceClose₹	533.40	100.30	219.00	135.81	256.05	402.00	795.00
IndustryIndustry	Pharma Formulations	Pharma Formulations	Pharma Formulations	Pharma Formulations	Pharma Formulations	Pharma Formulations	Pharma Formulations
Price To EarningsPE	11.08	23.11	24.86	165.62	28.87	22.31	20.11
Price To SalesPS	1.54	2.79	3.23	1.84	4.04	3.42	1.25
RevenueRevenueCr	694	332	237	397	147	141	364
Revenue Growth TTMRev Gr TTM%	10.2%	-12.8%	14.0%	7.5%		65.8%	11.4%
PAT Growth TTMPAT Gr TTM%	11.7%	540.7%	9.4%	-60.6%		51.2%	258.8%

	LINCOLN	THEMISMED	KILITCH	ZIMLAB	INFLUX	TLL	ALBERTDAVD
Market CapitalizationMkt CapCr	1,068	924	766	729	593	481	454
Close PriceClose₹	533.40	100.30	219.00	135.81	256.05	402.00	795.00
IndustryIndustry	Pharma Formulations	Pharma Formulations	Pharma Formulations	Pharma Formulations	Pharma Formulations	Pharma Formulations	Pharma Formulations
Price To EarningsPE	11.08	23.11	24.86	165.62	28.87	22.31	20.11
Price To SalesPS	1.54	2.79	3.23	1.84	4.04	3.42	1.25
RevenueRevenueCr	694	332	237	397	147	141	364
Revenue Growth TTMRev Gr TTM%	10.2%	-12.8%	14.0%	7.5%		65.8%	11.4%
PAT Growth TTMPAT Gr TTM%	11.7%	540.7%	9.4%	-60.6%		51.2%	258.8%

FY2026

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2026

Jun 26